Aliases & Classifications for Opioid Abuse

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse is related to drug dependence and schizophrenia. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Cocaine and Morphine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and b cells, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Opioid Abuse

Diseases related to Opioid Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 drug dependence 29.1 DRD2 OPRM1 PDYN
2 schizophrenia 28.5 CCK CCKAR DRD2 GRIN3B
3 episodic pain syndrome, familial, 1 10.5
4 chronic pain 10.3
5 functional gastric disease 10.3 CCK TRPV1
6 withdrawal disorder 10.3 OPRM1 PDYN
7 somatoform disorder 10.3 OPRM1 TRPV1
8 nasal cavity adenocarcinoma 10.3 CCK PDYN
9 pancreas disease 10.2 CCK TRPV1
10 stomach disease 10.2 CCK TRPV1
11 gastroesophageal reflux 10.2 CCK TRPV1
12 constipation 10.2 CCK OPRM1
13 exocrine pancreatic insufficiency 10.1 CCK CCKAR
14 irritable bowel syndrome 10.1 CCK TRPV1
15 morphine dependence 10.1 CCK OPRM1 TRPV1
16 cholelithiasis 10.1 CCK CCKAR
17 shipyard eye 10.1 PDYN SNORD50A
18 social phobia 9.9 CCK DRD2
19 aging 9.9
20 gallbladder disease 9.9 CCK CCKAR
21 dyspepsia 9.9 CCK CCKAR TRPV1
22 gastroparesis 9.9 CCK DRD2
23 gastrointestinal system disease 9.9 CCK CCKAR TRPV1
24 neonatal abstinence syndrome 9.9
25 pain agnosia 9.8 CCK OPRM1 PDYN TRPV1
26 agnosia 9.8 CCK OPRM1 PDYN TRPV1
27 specific developmental disorder 9.8 CCK OPRM1 PDYN TRPV1
28 heroin dependence 9.7 DRD2 OPRM1 PDYN
29 opiate dependence 9.7 DRD2 OPRM1 PDYN
30 cocaine dependence 9.7 DRD2 OPRM1 PDYN
31 arteries, anomalies of 9.7
32 coronary artery anomaly 9.7
33 substance abuse 9.7
34 cerebritis 9.7
35 eating disorder 9.5 CCK DRD2
36 alcohol dependence 9.5 CCK DRD2 OPRM1 PDYN
37 parkinson disease, late-onset 9.3 DRD2 PDYN TRPV1
38 body mass index quantitative trait locus 11 9.3 CCK CCKAR DRD2 TRPV1
39 disease of mental health 9.2 CCK DRD2 OPRM1 PDYN TRPV1
40 opioid addiction 9.1 CCK CCKAR DRD2 GRIN3B OPRM1

Graphical network of the top 20 diseases related to Opioid Abuse:



Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

MGI Mouse Phenotypes related to Opioid Abuse:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 OPRM1 PDYN PGAP3 CCK TRPV1 CCKAR
2 growth/size/body region MP:0005378 9.87 OPRM1 PDYN PGAP3 TRPV1 CCKAR DRD2
3 nervous system MP:0003631 9.8 OPRM1 PDYN CCK TRPV1 CCKAR DRD2
4 no phenotypic analysis MP:0003012 9.63 OPRM1 PDYN CCK TRPV1 DRD2 MAPK10
5 renal/urinary system MP:0005367 9.35 PGAP3 CCK TRPV1 CCKAR DRD2
6 taste/olfaction MP:0005394 8.8 TRPV1 CCKAR DRD2

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3 50-36-2 446220 5760
2
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
3
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
6
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
8 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
9 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
10 Anesthetics, Local Phase 4,Phase 2,Phase 3
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Opiate Alkaloids Phase 4,Phase 3,Phase 2
14 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
15 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
16 Psychotropic Drugs Phase 4,Phase 2
17 Analgesics, Non-Narcotic Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Antipyretics Phase 4
21 Antirheumatic Agents Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Ketorolac Tromethamine Phase 4
24 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Antipsychotic Agents Phase 4
26 Quetiapine Fumarate Phase 4 111974-72-2
27 Tranquilizing Agents Phase 4
28
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
29
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 93-14-1 3516
30
Heroin Approved, Illicit, Investigational Phase 3,Phase 2 561-27-3 5462328
31
Dopamine Approved Phase 2, Phase 3, Phase 1 51-61-6, 62-31-7 681
32
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 52485-79-7 644073 40400
33
Naloxone Approved, Vet_approved Phase 3,Phase 2 465-65-6 5284596
34
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
35 Antitussive Agents Phase 3,Phase 2,Phase 1
36 Chlorpheniramine, phenylpropanolamine drug combination Phase 3,Phase 2,Phase 1
37 Excitatory Amino Acid Antagonists Phase 3,Phase 2
38 Excitatory Amino Acids Phase 3,Phase 2
39 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
40 Respiratory System Agents Phase 3,Phase 2,Phase 1
41 Antiparkinson Agents Phase 2, Phase 3
42 Dopamine Agents Phase 2, Phase 3, Phase 1
43 Dopamine Uptake Inhibitors Phase 2, Phase 3,Phase 1
44 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 1
45 Vasoconstrictor Agents Phase 2, Phase 3,Phase 1
46 Buprenorphine, Naloxone Drug Combination Phase 2, Phase 3
47 Charcoal Phase 3
48
Armodafinil Approved, Investigational Phase 2 112111-43-0
49
Citalopram Approved Phase 2 59729-33-8 2771
50
Modafinil Approved, Investigational Phase 2 68693-11-8 4236

Interventional clinical trials:

(show top 50) (show all 72)

# Name Status NCT ID Phase Drugs
1 Multimodal Pain Management for Cesarean Delivery Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
2 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
3 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
4 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
5 Combined Therapy of Methadone and Dextromethrophan Unknown status NCT01189097 Phase 3 Dextromethorphan;Dextromethorphan
6 Prescription Opioid Addiction Treatment Study (POATS) Completed NCT00316277 Phase 3
7 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
8 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
9 Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction Not yet recruiting NCT03394911 Phase 3
10 Cell Phone Technology Targeting ART Adherence and Drug Use Unknown status NCT01884233 Phase 2
11 Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8 Unknown status NCT00218036 Phase 2 Modafinil 200mg;Modafinil 400mg;Citalopram 20mg;Citalopram 40mg;Placebo
12 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse Completed NCT01967641 Phase 2 buprenorphine/naloxone combination
13 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse Completed NCT00699010 Phase 2 Niacin;Oxycodone HCL plus Niacin;Placebo;Oxycodone HCL plus Niacin;Oxycodone HCl
14 Effective Treatment for Prescription Opioid Abuse Completed NCT00719095 Phase 2 buprenorphine taper followed by naltrexone maintenance
15 Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse Completed NCT00734461 Phase 2 oxycodone and naltrexone
16 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone Completed NCT01395784 Phase 2 pioglitazone
17 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users Completed NCT01030406 Phase 2 Drug A;Drug B;Drug C;Drug D;Placebo
18 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers Completed NCT01740414 Phase 2 MN-166 (50 mg) First;Placebo First
19 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Completed NCT01136356 Phase 1, Phase 2 buprenorphine;morphine
20 Prescription Opioid Effects in Abusers Versus Non-Abusers Completed NCT00158184 Phase 2 oxycodone 15 mg;oxycodone 30 mg;Placebo 0 mg
21 Medication Adherence Therapy for Opioid Abusing Pain Patients Completed NCT00249587 Phase 1, Phase 2 Methadone
22 Incentive-based Smoking Cessation for Methadone Patients Completed NCT00718835 Phase 2
23 The Discriminative Effects of Tramadol in Humans Completed NCT00499746 Phase 1, Phase 2 tramadol;placebo;Hydromorphone;Methylphenidate
24 Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids Completed NCT00218101 Phase 2 Buprenorphine
25 Contingency Management for Smoking in Substance Abusers Completed NCT00683033 Phase 2
26 Buprenorphine's Dose Response Curve Completed NCT00460239 Phase 2 Buprenorphine;Morphine;Placebo
27 NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study Recruiting NCT02692157 Phase 1, Phase 2 Placebo;NT-814 50 mg;NT-814 100 mg;NT-814 200 mg
28 Evaluation of Doxazosin to Alter the Abuse of Oxycodone Recruiting NCT03415581 Phase 2 Intranasal Oxycodone
29 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. Not yet recruiting NCT03389750 Phase 2 Intravenous Challege Drug
30 Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation Not yet recruiting NCT03420313 Phase 2 Buprenorphine/naloxone sublingual tablets
31 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users Completed NCT01380093 Phase 1 Placebo;MS Contin (morphine sulfate, controlled release);EMBEDA (morphine sulfate / naltrexone hydrochloride)
32 Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy Completed NCT01505101 Phase 1
33 Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine Completed NCT01367808 Phase 1 Placebo;vorikonazole;posakonazole
34 Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects Completed NCT01466803 Phase 1 Placebo;Vorikonazole
35 Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo Completed NCT01595867 Phase 1 Placebo;EMBEDA - morphine sulfate/ naltrexone hydrochloride;morphine sulfate CR crushed.
36 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder Recruiting NCT03143855 Phase 1 Lorcaserin;Placebo
37 Pain, Opioids and Pro-Inflammatory Immune Responses Terminated NCT01210066 Phase 1 Fentanyl
38 Study of Opioid Immunosuppressive Effects Unknown status NCT01881802
39 Methadone Maintenance Treatment Outcome Study in Taiwan Unknown status NCT01093248
40 Mobile Health Cognitive Stimulation in Heroin Users Unknown status NCT02308878
41 The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration Completed NCT00227357 On-site - buprenorphine/naloxone (Suboxone);Off-site - methadone or no agonist
42 Pilot Trial of Opioid Taper Support Completed NCT01883882
43 Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence Completed NCT00134888 Buprenorphine/naloxone
44 Aprepitant Effects on Oxycodone Response Completed NCT00999544 Aprepitant 0mg;Aprepitant 40mg;Aprepitant 200mg;Oxycodone 0mg, p.o.;Oxycodone 20mg, p.o.;Oxycodone 40mg, p.o.;Oxycodone 0mg, IN;Oxycodone 15mg, IN;Oxycodone 30mg, IN
45 Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts Completed NCT01668706
46 Taste Acuity and Caloric Intake After Acute Morphine Administration Completed NCT01763697
47 Pain Management Using Mobile Technology in Veterans With PTSD and TBI Completed NCT02237885
48 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111
49 Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR) Completed NCT01545778 Tapentadol IR;Oxycodone IR
50 Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients Completed NCT01570699

Search NIH Clinical Center for Opioid Abuse

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

38
Testes, Skin, B Cells, Heart, Brain

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 247)
# Title Authors Year
1
The FDA's Latest Response to Opioid Abuse and Overdose. ( 29280800 )
2018
2
The Public and the Opioid-Abuse Epidemic. ( 29298128 )
2018
3
Treating postoperative pain in the patient who is in recovery or remission from opioid abuse: Focus on Tapentadol. ( 29441514 )
2017
4
Parental Opioid Abuse: Barriers to Care, Policy, and Implications for Primary Care Pediatric Providers. ( 28760315 )
2017
5
Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain. ( 27782769 )
2017
6
Epidemiology of Opioid Abuse and Addiction. ( 28372767 )
2017
7
Toolkit aims to make adolescents aware of dangers of opioid abuse. ( 28483935 )
2017
8
Opioid Abuse And Poisoning: Trends In Inpatient And Emergency Department Discharges. ( 28971919 )
2017
9
The ALERRT(Ar) instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. ( 28448223 )
2017
10
Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. ( 28414990 )
2017
11
The Opioid Abuse Risk Screener predicts aberrant same-day urine drug tests and 1-year controlled substance database checks: A brief report. ( 29379630 )
2017
12
Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period. ( 29083966 )
2017
13
Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis. ( 28799863 )
2017
14
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). ( 28226334 )
2017
15
Screening tools to assess risk of opioid abuse in the Canadian primary healthcare setting. ( 28346282 )
2017
16
Review of Factors, Methods, and Outcome Definition in Designing Opioid Abuse Predictive Models. ( 29016966 )
2017
17
Corrigendum: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. ( 28318019 )
2017
18
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. ( 28226333 )
2017
19
An overview of available drugs for management of opioid abuse during pregnancy. ( 28203387 )
2017
20
Drivers of excess costs of opioid abuse among a commercially insured population. ( 28738684 )
2017
21
Collaboration Needed: Pain Care and Opioid Abuse. ( 27681886 )
2017
22
Intranasal tissue necrosis associated with opioid abuse: Case report and systematic review. ( 29280484 )
2017
23
Macroeconomic conditions and opioid abuse. ( 29128677 )
2017
24
The Economic Burden of Opioid Abuse: Updated Findings. ( 28345440 )
2017
25
Identification of Opioid Abuse or Dependence: No Tool Is Perfect. ( 28215952 )
2017
26
"I am in pain": is it really the magic formula to open the door of opioid abuse? ( 28726366 )
2017
27
Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. ( 29194445 )
2017
28
You never know when you'll need a Vicodin: An era of opioid abuse. ( 28400252 )
2017
29
Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. ( 28685864 )
2017
30
Chronic pain and opioid abuse: Factors associated with health-related quality of life. ( 29160596 )
2017
31
Opioid abuse in children: an emerging public health crisis in the United States! ( 28767106 )
2017
32
Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. ( 28086177 )
2017
33
Educational intervention for physicians to address the risk of opioid abuse. ( 29199396 )
2017
34
Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic. ( 28687816 )
2017
35
Considerations of prescription opioid abuse and misuse among older adults in West Virginia--An Under-Recognized Population at Risk. ( 27301154 )
2016
36
Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. ( 27669331 )
2016
37
President Obama Proposes $1.1 Billion in New Funding to Address the Prescription Opioid Abuse and Heroin Use Epidemic. ( 27301690 )
2016
38
The Surgeon's Roles in Stemming the Prescription Opioid Abuse Epidemic. ( 27156949 )
2016
39
A Community Partnership to Respond to the Heroin and Opioid Abuse Epidemic. ( 27012943 )
2016
40
Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. ( 27028915 )
2016
41
A comparison of an opioid abuse screening tool and prescription drug monitoring data in the emergency department. ( 26743334 )
2016
42
Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12. ( 27140989 )
2016
43
A Proactive Response to Prescription Opioid Abuse. ( 26845291 )
2016
44
The Surgeon's Role in Stemming the Prescription Opioid Abuse Epidemic. ( 27566462 )
2016
45
Development and preliminary validation of the Opioid Abuse Risk Screener. ( 28070401 )
2016
46
A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain. ( 26973529 )
2016
47
Mitigation Strategies for Opioid Abuse. ( 27406368 )
2016
48
Prescription Opioid Abuse and its Potential Role in Gross Dental Decay. ( 27492482 )
2016
49
Congress and Federal Agencies Address Opioid Abuse Epidemic, But Will New Initiatives Be Successful? ( 27504065 )
2016
50
Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. ( 27530870 )
2016

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

Pathways for Opioid Abuse

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.54 MAPK10 OPRM1 TRPV1
2 axon GO:0030424 9.5 CCK DRD2 OPRM1
3 perikaryon GO:0043204 9.33 CCK DRD2 OPRM1
4 axon terminus GO:0043679 9.26 DRD2 PDYN
5 neuronal cell body GO:0043025 9.26 CCK GRIN3B PDYN TRPV1
6 dendrite GO:0030425 9.02 CCK DRD2 OPRM1 PDYN TRPV1

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.85 CCK CCKAR DRD2 OPRM1 PDYN
2 sensory perception of pain GO:0019233 9.56 OPRM1 TRPV1
3 feeding behavior GO:0007631 9.55 CCKAR DRD2
4 release of sequestered calcium ion into cytosol GO:0051209 9.54 DRD2 TRPV1
5 response to cocaine GO:0042220 9.52 DRD2 OPRM1
6 negative regulation of adenylate cyclase activity GO:0007194 9.51 DRD2 OPRM1
7 calcium ion transmembrane transport GO:0070588 9.5 GRIN3B OPRM1 TRPV1
8 response to morphine GO:0043278 9.49 DRD2 OPRM1
9 regulation of sensory perception of pain GO:0051930 9.48 CCK OPRM1
10 response to light stimulus GO:0009416 9.43 DRD2 MAPK10
11 eating behavior GO:0042755 9.4 CCK OPRM1
12 temperature homeostasis GO:0001659 9.37 DRD2 TRPV1
13 behavioral response to ethanol GO:0048149 9.26 DRD2 OPRM1
14 sensory perception GO:0007600 9.16 OPRM1 PDYN
15 axonogenesis GO:0007409 9.13 CCK CCKAR DRD2
16 excitatory postsynaptic potential GO:0060079 8.92 DRD2 GRIN3B OPRM1 TRPV1

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CCK PDYN
2 cation channel activity GO:0005261 8.62 GRIN3B TRPV1

Sources for Opioid Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....